Loading
Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers.
KIR2DL1 (chromosome 19q13.42) is a receptor on NK cells for HLA-C alleles such as Cw4 and Cw6 that inhibits NK activity and so prevents lysis of the cell it recognises (UniProt P43626); KIR2DL3 does the same for HLA-Cw1, Cw3 and Cw7 (UniProt P43628). Lirilumab, an antibody against KIR2DL1, KIR2DL2 and KIR2DL3, was tested in phase 1/2 with nivolumab in solid tumours (NCT01714739); enrolment in myelodysplastic syndromes stopped after the sponsor decided not to pursue lirilumab for myeloid malignancies (NCT02599649), and a relapsed AML study ended because response rates did not reach the anticipated minimum of 30 percent (NCT02399917).
In plain words · Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers.
Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers.
Immunoglobulin-like receptors with long cytoplasmic tails (2DL, 3DL) inhibit through ITIMs; short-tailed KIRs activate. This record stands for the inhibitory KIR2DL group the antibody binds.
No product in this corpus aims at KIR2DL1 (inhibitory KIR) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 1995. Earliest sequence paper UniProt cites for the protein: Colonna et al, Science, 1995, "Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells". Source.
Sources: HGNC HGNC:6329 (approved symbol, name, aliases and cross-references); UniProt P43626 (protein name, function and tissue specificity)
Immunoglobulin-like receptors with long cytoplasmic tails (2DL, 3DL) inhibit through ITIMs; short-tailed KIRs activate. This record stands for the inhibitory KIR2DL group the antibody binds.
Query for this target: (TITLE:"KIR2DL1" OR ABSTRACT:"KIR2DL1" OR TITLE:"inhibitory KIR" OR ABSTRACT:"inhibitory KIR" OR TITLE:"KIR" OR ABSTRACT:"KIR" OR TITLE:"CD158a" OR ABSTRACT:"CD158a" OR TITLE:"p58.1" OR ABSTRACT:"p58.1" OR TITLE:"KIR2DL2" OR ABSTRACT:"KIR2DL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KIR2DL1 (inhibitory KIR), not a curated reading list.
Shares NKG2A (KLRC1), Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Nivolumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Nivolumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Nivolumab, Immune checkpoint inhibitors and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Immune checkpoint inhibitors and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.